Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
New words:
absolute, accidental, America, atropine, borrower, CBRN, chloride, clarification, Clarifying, commensurate, compensatory, counter, deficiency, detect, detected, dispute, effort, equine, extinguishment, fall, fever, FILOV, firm, functional, German, Germany, hemorrhagic, improperly, Ireland, Mapp, MCM, Ministry, misstatement, motion, neurotoxin, nominal, notably, obidoxime, objective, path, pediatric, PEI, recovery, regularly, reinstate, robust, shutdown, Simplifying, sr, store, succeed, sulfate, suspected, symptomatic, tolerability, Trobigard, viral, warfare, wholly
Removed:
ABThrax, accommodate, adjustment, allied, Ankara, announced, Anthim, antidote, antigen, appointment, assistance, assumed, Battelle, biotechnology, biowarfare, CBRNE, CODM, combat, combined, conform, consist, consulting, deduction, diversified, Emergard, enterprise, entitle, ERP, expanded, Explosive, favored, generated, GlaxoSmithKline, hematology, hierarchy, implementation, improve, Imputation, indirect, involving, ITAR, light, maker, meaningfully, Memorial, minimal, monitoring, MVAtor, narrower, neutralization, notification, novation, obiltoxaximab, oncology, philanthropic, plc, prime, protective, purified, raxibacumab, realigned, recast, reclassified, Refer, reimbursement, resource, responder, sheet, smaller, sponsor, stated, subcontract, Subtopic, surge, terminated, tested, turn, updated, utilization, VaxInnate, vector
Filing tables
Filing exhibits
Related press release
EBS similar filings
Filing view
External links
EXHIBIT 12
Ratio of Earnings to Fixed Charges | |||||||||||||||||||||||
Year to Date | |||||||||||||||||||||||
March 30, | Year Ended December 31, | ||||||||||||||||||||||
(in thousands) | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||||||||||||||||
Pretax income from continuing operations (1) | $ | 13,645 | $ | 99,221 | $ | 135,716 | $ | 84,194 | $ | 83,439 | $ | 68,011 | |||||||||||
Fixed charges | |||||||||||||||||||||||
Interest expense | 1,957 | 8,270 | 7,834 | 7,480 | 1,973 | 2,177 | |||||||||||||||||
Debt issuance cost | 382 | 1,526 | 1,564 | 3,290 | 319 | 67 | |||||||||||||||||
Total fixed charges (2) | 2,339 | 9,796 | 9,398 | 10,770 | 2,292 | 2,244 | |||||||||||||||||
Noncontrolling interest in pretax income (3) | - | - | - | - | 876 | 5,381 | |||||||||||||||||
Capitalized interest (4) | 401 | 2,179 | 2,875 | 2,530 | 1,973 | 2,177 | |||||||||||||||||
Earnings ((1) + (2) -(3) -(4)) | 15,583 | 106,838 | 142,239 | 92,434 | 82,882 | 62,697 | |||||||||||||||||
Fixed charges | 2,339 | 9,796 | 9,398 | 10,770 | 2,292 | 2,244 | |||||||||||||||||
Ratio of earnings to fixed charges | 6.7 | 10.9 | 15.1 | 8.6 | 36.2 | 27.9 | |||||||||||||||||
Coverage deficiency | - | - | - | - | - | - |